Fluticasone: Clinical Trials

46 trials of Fluticasone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

35 completed, 7 unknown, 1 not yet recruiting, 1 recruiting. 46 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 146Completed 35, Unknown 7, Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1
Phase 21Recruiting 1

Follow Fluticasone: new trials by email Literature Review of Fluticasone trials Research Report on Fluticasone

Trials (filtered) newest first · largest first

All 46 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Tolerability of Fluticasone Propionate 10% Nasal Insert in Participants With Chronic Allergic Rhinitis
Fluticasone Propionate (FP) 10% Nasal Insert - Chronic Allergic Rhinitis
Phase 1Not yet recruitingDianosic252026-11-012026-11-05
Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
TEV-56248, Fp MDPI - Asthma
Phase 1CompletedTeva Branded Pharmaceutical Products R&D, Inc.302024-05-162026-08-04
Advair HFA in Healthy and HAPE Predisposed Subjects
Advair HFA, Placebo - Altitude Edema
Phase 1 / Phase 2RecruitingUniversity of Colorado, Denver602023-12-122025-09-22
Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 500/50 - Bioequivalence
Phase 1UnknownRespirent Pharmaceuticals Co Ltd.342023-08-222023-09-06
Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 250/50 - Bioequivalence
Phase 1UnknownRespirent Pharmaceuticals Co Ltd.342023-08-012023-08-31
Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS 100/50 - Bioequivalence
Phase 1UnknownRespirent Pharmaceuticals Co Ltd.342023-02-172023-03-09
A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions
Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals, FLOVENT DISKUS - Asthma, Bioequivalence
Phase 1UnknownRespirent Pharmaceuticals Co Ltd.362022-05-112022-05-31
Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Test, Reference - Bioequivalence, Asthma
Phase 1UnknownRespirent Pharmaceuticals Co Ltd.182021-10-012021-10-20
A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions
Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals, FLOVENT DISKUS - Asthma, Bioequivalence
Phase 1UnknownRespirent Pharmaceuticals Co Ltd.502021-08-132021-08-26
A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Test, Reference - Bioequivalence, Asthma
Phase 1UnknownRespirent Pharmaceuticals Co Ltd.502021-01-182021-04-20
A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent, ADVAIR DISKUS® 500/50 - Bioequivalence
Phase 1CompletedRespirent Pharmaceuticals Co Ltd.342020-09-222021-01-20
A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent, ADVAIR DISKUS® 500/50 - Bioequivalence
Phase 1CompletedRespirent Pharmaceuticals Co Ltd.142020-09-012021-03-09
A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent, ADVAIR DISKUS® 250/50 - Bioequivalence
Phase 1CompletedRespirent Pharmaceuticals Co Ltd.142020-08-242021-01-20
A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Test Product, Reference Product - Bioequivalence
Phase 1CompletedRespirent Pharmaceuticals Co Ltd.342020-07-012021-03-09
A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade
Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals), Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK), Activated Charcoal suspension - Bioequivalence
Phase 1CompletedRespirent Pharmaceuticals Co Ltd.362019-10-012020-07-07
A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers
Test Product, Reference Product - Bioequivalence
Phase 1CompletedRespirent Pharmaceuticals Co Ltd.342019-05-212019-09-10
A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)
Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals, SERETIDE DISKUS® 250/50 inhalation powder/GSK, Activated Charcoal suspension - Bioequivalence
Phase 1CompletedRespirent Pharmaceuticals Co Ltd.362019-03-122019-06-05
A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Test Product, Reference Product - Bioequivalence
Phase 1CompletedRespirent Pharmaceuticals Co Ltd.342019-01-232019-03-27
A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers
Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg, ADVAIR DISKUS - Bioequivalence
Phase 1CompletedRespirent Pharmaceuticals Co Ltd.342018-11-202018-12-28
Study of REGN3500 and Dupilumab in Patients With Asthma
REGN3500, Dupilumab, Placebo - Asthma, Allergic
Phase 1CompletedRegeneron Pharmaceuticals322017-06-152020-01-18

Showing 20 of 46. Sign in to see all of them.

Conditions studied

Asthma (16)  ·  Pulmonary Disease, Chronic Obstructive (6)  ·  Rhinitis, Allergic (5)  ·  Altitude Sickness (1)  ·  Diabetes Mellitus (1)  ·  Hypoxia (1)  ·  Rhinitis, Allergic, Perennial (1)  ·  Rhinitis, Allergic, Seasonal (1)

Sponsors

Respirent Pharmaceuticals Co Ltd. (16)  ·  GlaxoSmithKline (5)  ·  Pfizer (3)  ·  Teva Branded Pharmaceutical Products R&D, Inc. (3)  ·  Egalet Ltd (2)  ·  Intech Biopharm Ltd. (2)  ·  MEDA Pharma GmbH & Co. KG (2)  ·  Merck Sharp & Dohme LLC (2)  ·  Dey (1)  ·  Dianosic (1)  ·  Joseph Dohar, MD (1)  ·  Kindeva Drug Delivery (1)  ·  Mannkind Corporation (1)  ·  Mundipharma Research Limited (1)  ·  Optinose US Inc. (1)

Countries

Greece (16)  ·  United States (9)  ·  United Kingdom (8)  ·  Germany (4)  ·  Australia (2)  ·  Taiwan (2)  ·  Ireland (1)  ·  Netherlands (1)  ·  South Korea (1)

Top investigators

Ioannis Stefanidis, Professor (9)  ·  Chrysoula Doxani, MD, MSc, PhD (6)  ·  Christine Kolb (2)  ·  W K Chang, M.D (2)  ·  Adrian J Stewart, BM, MRCGP, MFPM (1)  ·  Anders H. Boss (1)  ·  Chrysoula Doxani, Dr. (1)  ·  Cyril Clarke, BSc MB BS MFPM (1)  ·  In-Jin Jang, PhD (1)

Results publications

PMID 24168756, PMID 28626983, PMID 28933971, PMID 31732149

NIH funding

2016 (1)